ZeptoMetrix Launches H5N1 Control With Phage-Like Particle (PLP) Technology
BUFFALO, NEW YORK / ACCESS Newswire / June 23, 2025 / ZeptoMetrix® is pleased to announce the launch of NATtrol™ Influenza A H5N1 Quantitative Stock, a groundbreaking advancement in molecular diagnostic quality assurance. Leveraging phage-like particle encapsulated RNA technology, this product sets a new standard for accuracy and reliability in avian influenza (H5N1) detection, addressing critical gaps in laboratories' ability to validate end-to-end testing workflows.
As H5N1 outbreaks continue to rise globally, the need for robust quality control materials has never been greater. ZeptoMetrix's Influenza A H5N1 Quantitative Stock offers laboratories a comprehensive quality control material that requires RNA extraction, unlike traditional naked RNA products. This novel solution includes three encapsulated H5N1 gene segments within a phage-like particle, ensuring realistic validation of extraction, amplification, and detection steps.
"The ongoing H5N1 pandemic highlighted the urgent need for reliable diagnostic tools," said Dr. Karuna Sharma, PhD, Vice President & Chief Scientific Officer of Antylia Diagnostics division. "This launch represents a significant advancement in diagnostic quality control. By encapsulating RNA within a phage-like particle, we enable labs to have confidence in their results at every step. This is not just innovation; it is vital in the fight against H5N1 and other emerging RNA viruses."
NATtrol Influenza A H5N1 Quantitative Stock (Product Code: 0831198) is NATtrol inactivated to enhance stability and provided with precision quantification at 1,000,000 gene copies/mL of each gene segment, verified by digital PCR (dPCR). The ready-to-use 1 mL format integrates seamlessly with ZeptoMetrix's -STQ product line, streamlining workflow adoption.
More information on how to order and additional ZeptoMetrix products can be found at: www.zeptometrix.com
About ZeptoMetrix®
ZeptoMetrix, an Antylia Scientific company, is an established industry leader in the design, development, and delivery of innovative, quality solutions to the infectious disease diagnostics market. Our expertise and abilities in molecular diagnostics, including external quality controls, verification panels, proficiency panels, customized and OEM products/services, have set the industry standard for performance and reliability and make ZeptoMetrix the preferred choice for independent third-party quality control materials.
Product Page: https://www.zeptometrix.com/us/en/nattrol-influenza-a-h5n1-quantitative-stock-1-x-10-ml-15355
Contact Information
Andrew Zenger Global Product Managerandrew.zenger@antylia.com(716) 715-7417
SOURCE: ZeptoMetrix
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation With the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. ('Hims & Hers' or 'the Company') (NYSE: HIMS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Hims & Hers is the subject of an announcement by Novo Nordisk issued on June 23, 2025. According to Novo Nordisk, it is ending its relationship with the Company 'due to concerns about their illegal mass compounding and deceptive marketing.' According to the press release, 'the FDA resolved the Wegovy ® shortage based on its conclusion that Novo Nordisk is fully meeting current and projected nationwide demand for this medicine. In support of transitioning patients from knock-off compounded versions to authentic, FDA-approved Wegovy ® through NovoCare ® Pharmacy, Novo Nordisk began collaborating with telehealth companies. Over one month into the collaboration, Hims & Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk.' Based on this news, shares of Hims & Hers fell by more than 32.4% in afternoon trading on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Yahoo
3 hours ago
- Yahoo
Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025
How Parkinson's affects million – and why current treatments are not enough Continuous dopaminergic stimulation (CDS): a next-gen approach to Parkinson's care Serina's drug candidate SER-252 is designed to deliver continuous symptom relief Join Serina CEO Steve Ledger for this live event hosted by FORCE Family Office HUNTSVILLE, AL, June 23, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ('Serina') (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, is pleased to announce that Chief Executive Officer Steve Ledger will present at an upcoming FORCE Family Office investor webinar titled "New Drug Optimization Platform to Transform Parkinson's Care.' The Event is scheduled to take place on Thursday, June 26, 2025, at 12:00 p.m. ET / 9:00 a.m. PT. In this presentation, Mr. Ledger will discuss how advanced Parkinson's disease impacts millions of people worldwide by affecting their ability to move and maintain quality of life. He will highlight the limitations of current medications, which often wear off quickly or cause unwanted side effects like tremors or stiffness. SER-252 is Serina's propriety polymer conjugate of apomorphine, a clinically proven dopamine agonist, which is designed to deliver continuous dopaminergic stimulation (CDS), which aims to provide smoother, longer-lasting symptom control and greater convenience. The discussion will also explore the unique advantages of Serina's POZ Platform™, a next-generation drug optimization system with the potential to improve the safety, duration, and tolerability of Parkinson's treatments and other therapeutics. The webinar will be hosted by FORCE Family Office CEO, Steve Saltzstein, and include a Q&A session. Attendees may submit questions via the online chat feature during the event. To register for the complimentary event, please visit: Serina Therapeutics Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina's POZ Platform™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics, and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology. For more information, please visit About FORCE Family Office FORCE is the largest network of Family Offices, Foundations, Endowments, and individual accredited investors in the United States. They introduce members of their network to leaders of public companies and privately held businesses at the capital acquisition stage. In addition, they facilitate co-investment opportunities, information sharing, philanthropy, and networking among their elite, peer-to-peer community. More information can be found at Cautionary Statement Regarding Forward-Looking Statement This release contains forward-looking statements within the meaning of federal securities laws. These statements are based on management's current expectations, plans, beliefs, or forecasts for the future, and are subject to uncertainty and changes in circumstances. Any express or implied statements in this press release that are not statements of historical fact, including statements about the potential of Serina's POZ polymer technology, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions; whether and when regulatory authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on a myriad of factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any drug or vaccine candidates; and competitive developments. These risks as well as other risks are more fully discussed in Serina's Annual Report on Form 10-K, and Serina's other periodic reports and documents filed from time to time with the SEC. The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. For inquiries, please contact:Stefan Rileysriley@ 327-9630Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
TISSIUM Receives FDA De Novo Authorization for COAPTIUM® CONNECT in Atraumatic Sutureless Peripheral Nerve Repair
This regulatory milestone marks TISSIUM's entry into the U.S. market and establishes the foundation of the TISSIUM polymer platform for atraumatic tissue repairParis, France, Cambridge, USA, June 24, 2025 - TISSIUM, a MedTech company pioneering biomorphic programmable polymers for tissue reconstruction, today announced that the U.S. Food and Drug Administration (FDA) has granted De Novo marketing authorization for COAPTIUM® CONNECT with TISSIUM Light, a first-of-its-kind atraumatic sutureless solution for peripheral nerve repair. This authorization represents a pivotal regulatory milestone for TISSIUM, further validating its biopolymer platform and enabling U.S. commercialization of its first product. COAPTIUM® CONNECT is now the only FDA-authorized system designed for atraumatic sutureless nerve coaptation. Christophe Bancel, Co-Founder and CEO of TISSIUM said: 'This FDA marketing authorization validates over a decade of scientific and clinical commitment to developing next-generation solutions in tissue reconstruction. COAPTIUM® CONNECT is the first demonstration of the transformative potential of our polymer platform and an important step in making atraumatic tissue repair available to patients.' Peripheral nerve injuries affect hundreds of thousands of patients annually and are typically repaired using microsurgical sutures. However, this approach presents limitations—including technical complexity, risk of additional trauma, and variable outcomes. COAPTIUM® CONNECT addresses these challenges by offering a reproducible, atraumatic sutureless alternative that preserves nerve integrity and simplifies the coaptation process1. In a recent clinical study on 12 patients with digital nerve injuries, COAPTIUM® CONNECT achieved 100% procedural success, defined as successful atraumatic sutureless coaptation using the polymer-assisted coaptation device, with all patients regaining full flexion and extension of the injured digit and reporting no pain 12 months after the procedure1. TISSIUM plans to initiate commercial rollout of COAPTIUM® CONNECT in the coming months. The COAPTIUM® CONNECT System leverages TISSIUM's unique biopolymer platform, invented by Maria Pereira, Jeffrey Karp and Robert Langer at the MIT and Brigham & Women's Hospital, using its bioresorbable light-activated surgical polymer and its 3D-printed polymer chamber. Maria Pereira, Co-Founder and Chief Innovation Officer, said: 'This first product illustrates the technical versatility and the potential of the TISSIUM polymer platform, not only in peripheral nerve repair where other solutions are currently under development, but also in other surgical applications, such as atraumatic hernia repair and cardiovascular sealing.' *** About TISSIUM TISSIUM is a clinical and commercial stage MedTech company based in Paris, France, Cambridge, USA, and with a manufacturing site in Roncq, France. The company is pioneering a proprietary platform of fully biosynthetic, biomorphic, programmable, elastomeric polymers designed to address critical unmet needs in atraumatic tissue repair and tissue reconstruction. TISSIUM's diversified pipeline includes seven products across three core verticals: sutureless nerve repair, atraumatic hernia repair, and cardiovascular sealants. Each solution is designed to optimize tissue repair through controlled and consistent procedures with specialized delivery and activation devices to maximize the performance and usability of its products. Founded in 2013, TISSIUM is built on breakthrough research and intellectual property originating from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women's Hospital). For more information, please visit and follow us on LinkedIn: TISSIUM. *** Contacts Investor relationsRomain Attard – Chief Financial Officer rattard@ Press tissium@ A Sutureless Approach to Nerve Repair: Results from a Clinical Study in Digital Nerves, Randi Bindra, Journal of Hand Surgery, submitted 2025Attachment 20250624 - TISSIUM_FDA DeNovo announcementError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
